AACC expresses concern about rush to pass VALID Act

By LabPulse.com staff writers

June 7, 2022 -- The American Association for Clinical Chemistry (AACC) on Monday announced that it has joined more than 100 medical and patient organizations to express concern that the U.S. Senate Committee on Health, Education, Labor and Pensions (HELP) is rushing to pass the Verifying Accurate Leading-edge IVCT Development (VALID) Act.

The bill would limit patient access to laboratory-developed tests and the diagnoses these tests enable.

The medical and patient communities are specifically urging Congress to remove the VALID Act from the FDA Safety and Landmark Advancements (FDASLA) Act, legislation that the Senate is on the cusp of ratifying and could pass this week, AACC said.

AACC lobbies against greater regulation of lab-developed tests
The American Association for Clinical Chemistry (AACC) is urging Congress to not include a bill to mandate greater regulatory oversight of laboratory-developed...
CAP weighs in on U.S. Senate's FDA user fee authorization bill
The College of American Pathologists (CAP) has released remarks regarding the draft U.S. Food and Drug Administration (FDA) user fee authorization bill...
AACC criticizes FDA over warning on prenatal genetic tests
The American Association for Clinical Chemistry (AACC) has criticized the U.S. Food and Drug Administration over its recent warning that genetic noninvasive...
AMP calls for thorough evaluation of VALID Act
The Association for Molecular Pathology (AMP) recently called on the U.S. Congress to allow for a thorough evaluation of the Verifying Accurate Leading-edge...
Could COVID-19 end standoff on tests developed in laboratories?
During the COVID-19 pandemic, research and clinical laboratories have been working overtime to develop tests that would help them identify and understand...

Copyright © 2022 LabPulse.com

Last Updated lo 6/9/2022 6:36:47 AM